Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Intraperitoneal Pressure Measurements Survey in Pediatric Centers

NCT07339709 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-07-16
Last updated
2026-01-14

Condition(s) studied

Pediatric Renal Failure

Study summary

Intraperitoneal pressure (IPP) is an objective measurement used to assess tolerance to fluid volume. IPP has been shown to be strongly correlated with intraperitoneal dialysate volume as well as anthropometric parameters. In observational studies conducted in adults, an IPP greater than 13-14 cmH2O was associated with an increased risk of peritonitis, initiation of hemodialysis, or death.

Measuring IPP is therefore a tool to optimize dialysis prescriptions. However, this measurement is not well standardized, and there is limited scientific evidence regarding its impact on patient management.

Measuring IPP is a tool to optimize dialysis prescriptions. However, this measurement is not well standardized, and there is limited scientific evidence regarding its impact on patient management. Some centers do not perform any measurements, others perform them monthly, and some only during peritoneal equilibration tests.

The hypothesis of this research is to highlight current practices and experiences in measuring intraperitoneal pressures in children undergoing peritoneal dialysis in different European dialysis centers, in order to improve practices regarding PIP prescription.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- Healthcare professional working in a European dialysis center Exclusion Criteria: \- Refusal to participate in the study.

Primary outcome measure(s)

  • Review of current practices in measuring intraperitoneal pressures in children undergoing peritoneal dialysis — Up to 12 months
    This study aims to provide an overview of current experiences in measuring intraperitoneal pressures in children undergoing peritoneal dialysis in different European dialysis centers.

Trial sites (1)

FacilityCityRegionStatus
Service de pédiatrie 1 - CHU de Strasbourg - France Strasbourg France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07339709 on ClinicalTrials.gov ↗ ← All trials in France